

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
24 July 2025 (24.07.2025)



(10) International Publication Number
WO 2025/153530 A1

(51) International Patent Classification:

A61K 48/00 (2006.01) C12N 9/22 (2006.01)
C07K 14/00 (2006.01) C12N 15/63 (2006.01)
C12N 15/864 (2006.01)

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(21) International Application Number:

PCT/EP2025/050881

(22) International Filing Date:

15 January 2025 (15.01.2025)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/621,235 16 January 2024 (16.01.2024) US

(71) Applicant: NOVO NORDISK A/S [DK/DK]; Novo Alle
1, 2880 Bagsværd (DK).

(72) Inventors: HALLINAN, Jazmine, Pua'nani; Novo
Nordisk Research Centre Seattle Inc. 530 Fairview Ave
N, Seattle, Washington 98109 (US). HAVENS, Kyle, An-
drew; 800 Indiana St Apt 430, San Francisco, California
94107 (US). MOORE, John, Christopher; Novo Nordisk
Research Centre Seattle Inc. 530 Fairview Ave N, Seat-
tle, Washington 98109 (US). SCALLEY-KIM, Michelle,
Louise; Novo Nordisk Research Centre Seattle Inc. 530
Fairview Ave N, Seattle, Washington 98109 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN,
WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: ALBUMIN-TARGETED ENDONUCLEASES, COMPOSITIONS, AND METHODS OF USE

(57) Abstract: The present disclosure provides improved genome editing compositions and methods for editing and ALB gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of a disease, e.g., by enabling insertion of a therapeutic polypeptide/protein, factor, or antibody into the ALB locus.

WO 2025/153530 A1